Update shared on10 Aug 2025
Fair value Decreased 27%RxSight’s consensus price target has been significantly reduced to $8.89 as analysts cite ongoing quarterly misses, slower customer adoption, plateauing utilization rates, and uncertainty around commercial strategy execution.
Analyst Commentary
- Multiple bearish analysts cite consecutive quarterly misses and lowered guidance as primary concerns impacting RxSight's outlook.
- Prolonged capital equipment selling cycles and slower-than-expected ramp-up of new customers have dampened near-term growth prospects.
- Existing customer utilization rates have plateaued, and sales of the Light Delivery Device segment have been notably soft.
- Inventory analysis indicates normal consignment levels, but unexpected softness in Light Adjustable Lens sales during March raised red flags.
- Analysts question the effectiveness and timing of RxSight’s new commercial strategy, highlighting structural challenges and uncertainty around the pace of potential recovery.
What's in the News
- A lawsuit has been filed against RxSight and senior executives for alleged securities law violations, citing undisclosed adoption challenges and LAL utilization slowdown that led to major revenue forecast cuts and a sharp stock price decline.
- RxSight provided preliminary Q2 2025 revenue guidance of $33.6 million (down 4% YoY, down 11% QoQ), with sales of 27,380 Light Adjustable Lenses (up 13% YoY) and 40 Light Delivery Devices (down 49% YoY); installed LDD base expanded 34% YoY to 1,084.
- The company lowered its full-year 2025 revenue outlook to $120–130 million, a downward revision from prior guidance of $160–175 million, implying a 7%–14% decline from 2024.
- RxSight reaffirmed its lowered 2025 revenue guidance of $120–130 million.
- Q2 2025 earnings call was held.
Valuation Changes
Summary of Valuation Changes for RxSight
- The Consensus Analyst Price Target has significantly fallen from $12.22 to $8.89.
- The Consensus Revenue Growth forecasts for RxSight has significantly fallen from 5.3% per annum to 1.0% per annum.
- The Future P/E for RxSight has significantly fallen from 30.63x to 26.01x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.